메뉴 건너뛰기




Volumn 56, Issue 7, 2015, Pages 1938-1948

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms

(15)  Mughal, Tariq I a   Barbui, Tiziano b   Abdel Wahab, Omar c   Kralovics, Robert d   Jamieson, Catriona e   Kvasnicka, Hans Michael f   Mullaly, Ann g   Rampal, Raajit c   Mesa, Ruben h   Kiladjian, Jean Jacques i   Deininger, Michael j   Prchal, Josef j   Hehlmann, Rüdiger k   Saglio, Giuseppe l   Van Etten, Richard A m  


Author keywords

Molecular genetics; Myeloid leukemias and dysplasias; Myeloproliferative disorders; Prognostication; Signaling therapies

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

EID: 84938149109     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.974594     Document Type: Review
Times cited : (4)

References (63)
  • 1
    • 84899748354 scopus 로고    scopus 로고
    • Current pre-clinical and clinical advances in the BCR-ABL1-positive and-negative chronic myeloproliferative neoplasms
    • Mughal TI, Vannucchi AM, Soverini S, et al. Current pre-clinical and clinical advances in the BCR-ABL1-positive and-negative chronic myeloproliferative neoplasms. Haematologica 2014;99:797-803.
    • (2014) Haematologica , vol.99 , pp. 797-803
    • Mughal, T.I.1    Vannucchi, A.M.2    Soverini, S.3
  • 2
    • 0035810147 scopus 로고    scopus 로고
    • Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
    • Druker B, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1042.
    • (2001) N Engl J Med , vol.344 , pp. 1031-1042
    • Druker, B.1    Talpaz, M.2    Resta, D.J.3
  • 3
    • 84902507360 scopus 로고    scopus 로고
    • Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: Efficacy based on early response
    • Cortes J, Hochhaus A, Kim DW, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2013;122(Suppl. 1): Abstract 65.
    • (2013) Blood , vol.122 , pp. 65
    • Cortes, J.1    Hochhaus, A.2    Kim, D.W.3
  • 4
    • 84902484777 scopus 로고    scopus 로고
    • ENESTnd update: Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes
    • Saglio G, Hochhaus A, Hughes T, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013;122(Suppl. 1): Abstract 92.
    • (2013) Blood , vol.122 , pp. 92
    • Saglio, G.1    Hochhaus, A.2    Hughes, T.3
  • 5
    • 17844383458 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera
    • James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144-1148.
    • (2005) Nature , vol.434 , pp. 1144-1148
    • James, C.1    Ugo, V.2    Le Couedic, J.P.3
  • 6
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
    • (2010) N Engl J Med , vol.363 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 7
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799-807.
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 8
    • 84857837774 scopus 로고    scopus 로고
    • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
    • (2012) N Engl J Med , vol.366 , pp. 787-798
    • Harrison, C.1    Kiladjian, J.J.2    Al-Ali, H.K.3
  • 9
    • 84901714382 scopus 로고    scopus 로고
    • Integrated geneomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
    • Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated geneomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014;123:e123-e133.
    • (2014) Blood , vol.123 , pp. e123-e133
    • Rampal, R.1    Al-Shahrour, F.2    Abdel-Wahab, O.3
  • 10
    • 84890372480 scopus 로고    scopus 로고
    • Somatic mutations of calreticulin in myeloproliferative neoplasms
    • Klampf T, Gisslinger H, Hanutyunyan A, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369:2379-2390.
    • (2013) N Engl J Med , vol.369 , pp. 2379-2390
    • Klampf, T.1    Gisslinger, H.2    Hanutyunyan, A.3
  • 11
    • 84890328032 scopus 로고    scopus 로고
    • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
    • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
    • (2013) N Engl J Med , vol.369 , pp. 2391-2405
    • Nangalia, J.1    Massie, C.E.2    Baxter, E.J.3
  • 12
    • 84902589906 scopus 로고    scopus 로고
    • From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms
    • Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714-3719.
    • (2014) Blood , vol.123 , pp. 3714-3719
    • Cazzola, M.1    Kralovics, R.2
  • 13
    • 84902669989 scopus 로고    scopus 로고
    • Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms
    • Duek A, Lundberg P, Shimizu T, et al. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F driven mouse model of myeloproliferative neoplasms. Blood 2014;123 : 3943-3950.
    • (2014) Blood , vol.123 , pp. 3943-3950
    • Duek, A.1    Lundberg, P.2    Shimizu, T.3
  • 14
    • 32844461437 scopus 로고    scopus 로고
    • Why does CML evolve from a chronic phase to blast phase?
    • Mughal TI, Goldman JM. Why does CML evolve from a chronic phase to blast phase? Front Biosci 2006;1:198-208.
    • (2006) Front Biosci , vol.1 , pp. 198-208
    • Mughal, T.I.1    Goldman, J.M.2
  • 15
    • 52649131772 scopus 로고    scopus 로고
    • The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms
    • Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 2008;112:1628-1637.
    • (2008) Blood , vol.112 , pp. 1628-1637
    • Tam, C.S.1    Nussenzveig, R.M.2    Popat, U.3
  • 16
    • 84878225843 scopus 로고    scopus 로고
    • Treatment outcomes following leukemic transformation in Ph-negative myeloproliferative neoplasms
    • Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Ph-negative myeloproliferative neoplasms. Blood 2013;121:2725-2733.
    • (2013) Blood , vol.121 , pp. 2725-2733
    • Kennedy, J.A.1    Atenafu, E.G.2    Messner, H.A.3
  • 17
    • 84861082246 scopus 로고    scopus 로고
    • Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
    • Zhang SJ, RampalR, ManshouriT, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012;119:4480-4485.
    • (2012) Blood , vol.119 , pp. 4480-4485
    • Zhang, S.J.1    Rampal, R.2    Manshouri, T.3
  • 18
    • 84872522380 scopus 로고    scopus 로고
    • ADAR-1 promotes malignant progenitor programming in chronic myeloid leukemia
    • Jiang Q, Crews LA, Barrett CL, et al. ADAR-1 promotes malignant progenitor programming in chronic myeloid leukemia. Proc Natl Acad Sci USA 2013;110:1041-1046.
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 1041-1046
    • Jiang, Q.1    Crews, L.A.2    Barrett, C.L.3
  • 19
    • 84938054376 scopus 로고    scopus 로고
    • Development of a murine model for leukemic transformation of myeloproliferative neoplasms for preclinical therapeutic studies
    • Rampal R, Pandey S, Abdel-Wahab O, et al. Development of a murine model for leukemic transformation of myeloproliferative neoplasms for preclinical therapeutic studies. Blood 2012;120(Suppl. 1): Abstract 808.
    • (2012) Blood , vol.120 , pp. 808
    • Rampal, R.1    Pandey, S.2    Abdel-Wahab, O.3
  • 20
    • 84898402032 scopus 로고    scopus 로고
    • The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera
    • Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2V617F and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 2014;28:938-941.
    • (2014) Leukemia , vol.28 , pp. 938-941
    • Wang, L.1    Swierczek, S.I.2    Lanikova, L.3
  • 21
    • 84898472976 scopus 로고    scopus 로고
    • Whole-exome sequencing of polycythemia vera revealed driver genes and somatic mutation shared by T cells and granulocytes
    • Wang L, Swierczek SI, Drummond J, et al. Whole-exome sequencing of polycythemia vera revealed driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 2014;28: 935-938.
    • (2014) Leukemia , vol.28 , pp. 935-938
    • Wang, L.1    Swierczek, S.I.2    Drummond, J.3
  • 22
    • 84938143461 scopus 로고    scopus 로고
    • Order matters: Mutation order influences tumour evolution and stem cell potency by altering transcriptional consequences of the second mutation
    • EHA Abstract LBA2434
    • Kent D, Green AR. Order matters: mutation order influences tumour evolution and stem cell potency by altering transcriptional consequences of the second mutation. Haematologica 2014: EHA Abstract LBA2434.
    • (2014) Haematologica
    • Kent, D.1    Green, A.R.2
  • 23
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
    • (2009) Blood , vol.114 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3
  • 24
    • 74049112732 scopus 로고    scopus 로고
    • Prodromal myeloproliferative neoplasms: The 2008 WHO classification
    • Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2008;85: 62-69.
    • (2008) Am J Hematol , vol.85 , pp. 62-69
    • Kvasnicka, H.M.1    Thiele, J.2
  • 25
    • 84875474755 scopus 로고    scopus 로고
    • JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis
    • Barosi G, Poletto V, Massa M, et al. JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. PLoS One 2013;8:e59791.
    • (2013) PLoS One , vol.8 , pp. e59791
    • Barosi, G.1    Poletto, V.2    Massa, M.3
  • 26
    • 33745079673 scopus 로고    scopus 로고
    • Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl
    • Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006;19:413-437.
    • (2006) Best Pract Res Clin Haematol , vol.19 , pp. 413-437
    • Thiele, J.1    Kvasnicka, H.M.2    Vardiman, J.3
  • 27
    • 16344385524 scopus 로고    scopus 로고
    • Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns?
    • Thiele J, Kvasnicka HM, Diehl V. Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 2005; 20:633-644.
    • (2005) Histol Histopathol , vol.20 , pp. 633-644
    • Thiele, J.1    Kvasnicka, H.M.2    Diehl, V.3
  • 28
    • 79957611312 scopus 로고    scopus 로고
    • Essential thrombo-cythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification
    • Thiele J, Kvasnicka HM, Mullauer L, et al. Essential thrombo-cythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011;117:5710-5718.
    • (2011) Blood , vol.117 , pp. 5710-5718
    • Thiele, J.1    Kvasnicka, H.M.2    Mullauer, L.3
  • 29
    • 84892882972 scopus 로고    scopus 로고
    • Masked polycythemia vera (mPV): Results of an international study
    • Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol 2014;89: 52-54.
    • (2014) Am J Hematol , vol.89 , pp. 52-54
    • Barbui, T.1    Thiele, J.2    Gisslinger, H.3
  • 30
    • 84873515382 scopus 로고    scopus 로고
    • Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up
    • Ejerblad E, Kvasnicka HM, Thiele J, et al. Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up. Hematology 2013; 18:8-13.
    • (2013) Hematology , vol.18 , pp. 8-13
    • Ejerblad, E.1    Kvasnicka, H.M.2    Thiele, J.3
  • 31
    • 84876515240 scopus 로고    scopus 로고
    • Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: The ANAHYDRET study, a randomized controlled trial
    • Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013; 121:1720-1728.
    • (2013) Blood , vol.121 , pp. 1720-1728
    • Gisslinger, H.1    Gotic, M.2    Holowiecki, J.3
  • 32
    • 84938143462 scopus 로고    scopus 로고
    • European LeukemiaNet (ELN) consensus criteria for therapy response based on bone marrow features in patients with myelofibrosis
    • (in press)
    • Kvasnicka HM, Thiele J, Orazi A, et al. European LeukemiaNet (ELN) consensus criteria for therapy response based on bone marrow features in patients with myelofibrosis. J Clin Oncol to Leukemia (in press).
    • J Clin Oncol to Leukemia
    • Kvasnicka, H.M.1    Thiele, J.2    Orazi, A.3
  • 33
    • 0037114625 scopus 로고    scopus 로고
    • Polycythemia vera: Myths, mechanisms, and management
    • Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-4290.
    • (2002) Blood , vol.100 , pp. 4272-4290
    • Spivak, J.L.1
  • 34
    • 84893964717 scopus 로고    scopus 로고
    • Masked polycythemia vera diagnosed according to WHO and BCSH classification
    • Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol 2014;89:199-202.
    • (2014) Am J Hematol , vol.89 , pp. 199-202
    • Barbui, T.1    Thiele, J.2    Carobbio, A.3
  • 35
    • 84859643082 scopus 로고    scopus 로고
    • Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
    • Deshpande A, Reddy MM, Schade GOM, et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012;26:708-715.
    • (2012) Leukemia , vol.26 , pp. 708-715
    • Deshpande, A.1    Reddy, M.M.2    Schade, G.O.M.3
  • 36
    • 84899696697 scopus 로고    scopus 로고
    • Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors
    • Marty C, Saint-Martin C, Pecquet C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014;123:1372-1383.
    • (2014) Blood , vol.123 , pp. 1372-1383
    • Marty, C.1    Saint-Martin, C.2    Pecquet, C.3
  • 37
    • 84898990827 scopus 로고    scopus 로고
    • Molecular pathways: Molecular basis for sensitivity and resistance to JAK kinase inhibitors
    • Meyer S, Levine R. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014;20:2051-2059.
    • (2014) Clin Cancer Res , vol.20 , pp. 2051-2059
    • Meyer, S.1    Levine, R.2
  • 38
    • 84924809368 scopus 로고    scopus 로고
    • Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain
    • Andreoli A, Verger E, Robin M, et al. Clinical resistance to ruxolitinib is more frequent in patients without MPN-associated mutations and is rarely due to mutations in the JAK2 kinase drug-binding domain. Blood 2013;122(Supp. 1): Abstract 1591.
    • (2013) Blood , vol.122 , pp. 1591
    • Andreoli, A.1    Verger, E.2    Robin, M.3
  • 39
    • 84856932936 scopus 로고    scopus 로고
    • Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
    • Weigert O, Lane A, Bird J, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012;209:259-273.
    • (2012) J Exp Med , vol.209 , pp. 259-273
    • Weigert, O.1    Lane, A.2    Bird, J.3
  • 40
    • 84865735256 scopus 로고    scopus 로고
    • Heterdimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
    • Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterdimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-159.
    • (2012) Nature , vol.489 , pp. 155-159
    • Koppikar, P.1    Bhagwat, N.2    Kilpivaara, O.3
  • 41
    • 84891303523 scopus 로고    scopus 로고
    • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    • Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
    • (2013) Blood , vol.122 , pp. 4047-4053
    • Cervantes, F.1    Vannucchi, A.M.2    Kiladjian, J.-J.3
  • 42
    • 84901007488 scopus 로고    scopus 로고
    • Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I
    • Verstovsek S, Mesa R, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood 2013;122(Suppl. 1): Abstract 396.
    • (2013) Blood , vol.122 , pp. 396
    • Verstovsek, S.1    Mesa, R.2    Gotlib, J.3
  • 43
    • 84897566182 scopus 로고    scopus 로고
    • Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy
    • Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122(Suppl. 1): Abstract 4055.
    • (2013) Blood , vol.122 , pp. 4055
    • Kvasnicka, H.M.1    Thiele, J.2    Bueso-Ramos, C.E.3
  • 44
    • 84894237348 scopus 로고    scopus 로고
    • Results of a randomized, double-blind, placebo-controlled phase III study (Jakarta) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF)
    • Harrison CN, Cortes JE, Cervantes F, Mesa et al. Results of a randomized, double-blind, placebo-controlled phase III study (Jakarta) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood 2013;122(Suppl. 1): Abstract 393.
    • (2013) Blood , vol.122 , pp. 393
    • Harrison, C.N.1    Cortes, J.E.2    Cervantes, F.3    Mesa4
  • 45
    • 84901017205 scopus 로고    scopus 로고
    • Symptom burden and health-related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with fedratinib (SAR302503) in a phase III study (Jakarta)
    • MesaR, Cortes JE, Cervantes F, et al. Symptom burden and health-related quality of life (HRQoL) in patients with myelofibrosis (MF) treated with fedratinib (SAR302503) in a phase III study (Jakarta). Blood 2013;122(Suppl. 1): Abstract 4061.
    • (2013) Blood , vol.122 , pp. 4061
    • Mesa, R.1    Cortes, J.E.2    Cervantes, F.3
  • 46
    • 84896937999 scopus 로고    scopus 로고
    • Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: Interim results from a phase II study (Jakarta-2)
    • Harrison C, Schaap NP, Zweegman S, et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate-or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (Jakarta-2). Blood 2013;122(Suppl. 1): Abstract 661.
    • (2013) Blood , vol.122 , pp. 661
    • Harrison, C.1    Schaap, N.P.2    Zweegman, S.3
  • 47
    • 84907912086 scopus 로고    scopus 로고
    • The Janus kinase 2 inhibtor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy
    • Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibtor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metab Dispos 2014;42: 1656-1662.
    • (2014) Drug Metab Dispos , vol.42 , pp. 1656-1662
    • Zhang, Q.1    Zhang, Y.2    Diamond, S.3
  • 48
    • 84900870280 scopus 로고    scopus 로고
    • Pacritinib, a dual JAK2/FLT3 inhibitor: An integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts < 100,000/liI
    • Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts < 100,000/liI. Blood 2013;122(Suppl. 1): Abstract 395.
    • (2013) Blood , vol.122 , pp. 395
    • Dean, J.P.1    Cernohous, P.2    Komrokji, R.S.3
  • 49
    • 84878951826 scopus 로고    scopus 로고
    • Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27:1322-1327.
    • (2013) Leukemia , vol.27 , pp. 1322-1327
    • Pardanani, A.1    Laborde, R.R.2    Lasho, T.L.3
  • 50
    • 84896985472 scopus 로고    scopus 로고
    • Phase i study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
    • Verstovsek S, Mesa RA, Salama ME, et al. Phase I study of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013;122(Suppl. 1): Abstract 665.
    • (2013) Blood , vol.122 , pp. 665
    • Verstovsek, S.1    Mesa, R.A.2    Salama, M.E.3
  • 51
    • 84896941348 scopus 로고    scopus 로고
    • BMS-911543, a selective JAK2 inhibitor: A multicenter phase 1/2a study in myelofibrosis
    • Pardanani A, Roberts AW, Seymour JF, et al. BMS-911543, a selective JAK2 inhibitor: a multicenter phase 1/2a study in myelofibrosis. Blood 2013;122(Suppl. 1): Abstract 664.
    • (2013) Blood , vol.122 , pp. 664
    • Pardanani, A.1    Roberts, A.W.2    Seymour, J.F.3
  • 52
    • 84896917435 scopus 로고    scopus 로고
    • An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis
    • Mascarenhas J, Talpaz M, Gupta V, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013;122(Suppl. 1): Abstract 663.
    • (2013) Blood , vol.122 , pp. 663
    • Mascarenhas, J.1    Talpaz, M.2    Gupta, V.3
  • 53
    • 84897000773 scopus 로고    scopus 로고
    • Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis
    • Tefferi A, Begna K, Laborde RR, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. Blood 2013; 122(Suppl. 1): Abstract 662.
    • (2013) Blood , vol.122 , pp. 662
    • Tefferi, A.1    Begna, K.2    Laborde, R.R.3
  • 54
    • 84927968894 scopus 로고    scopus 로고
    • Does anything work for anemia in myelofibrosis?
    • Birgegard G. Does anything work for anemia in myelofibrosis? Best Pract Res Clin Haematol 2014;27:175-185.
    • (2014) Best Pract Res Clin Haematol , vol.27 , pp. 175-185
    • Birgegard, G.1
  • 55
    • 84892718446 scopus 로고    scopus 로고
    • Deep molecular response in chronic myeloid leukemia: The new goal therapy?
    • Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal therapy? Clin Cancer Res 2014;20:310-322.
    • (2014) Clin Cancer Res , vol.20 , pp. 310-322
    • Mahon, F.X.1    Etienne, G.2
  • 56
    • 84880790088 scopus 로고    scopus 로고
    • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts
    • Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.
    • (2013) Blood , vol.121 , pp. 4439-4442
    • Experts in Chronic Myeloid Leukemia1
  • 57
    • 84881298446 scopus 로고    scopus 로고
    • EuropeanLeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
    • BaccaraniM, DeiningerMW, RostiG, et al. EuropeanLeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
    • (2013) Blood , vol.122 , pp. 872-884
    • Baccarani, M.1    Deininger, M.W.2    Rosti, G.3
  • 58
    • 84905387521 scopus 로고    scopus 로고
    • Molecular response in CML: Where is the bar?
    • Baccarani M, Soverini S. Molecular response in CML: where is the bar? Blood 2014;124:469-471.
    • (2014) Blood , vol.124 , pp. 469-471
    • Baccarani, M.1    Soverini, S.2
  • 59
    • 84897574239 scopus 로고    scopus 로고
    • Deep molecular response is reached by the majority of patients treated with imatinb, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV
    • Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinb, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol 2014;32:415-423.
    • (2014) J Clin Oncol , vol.32 , pp. 415-423
    • Hehlmann, R.1    Muller, M.C.2    Lauseker, M.3
  • 60
    • 84896622957 scopus 로고    scopus 로고
    • Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
    • Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 2014:123:1309-1318.
    • (2014) Blood , vol.123 , pp. 1309-1318
    • Kantarjian, H.M.1    Cortes, J.E.2    Kim, D.W.3
  • 61
    • 52649104330 scopus 로고    scopus 로고
    • Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease
    • Agarwal A, Bumm TG, Corbin AS, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008;112:1960-1970.
    • (2008) Blood , vol.112 , pp. 1960-1970
    • Agarwal, A.1    Bumm, T.G.2    Corbin, A.S.3
  • 62
    • 84938143463 scopus 로고    scopus 로고
    • P27 and leukemia: Cell cycle and beyond
    • Sep 10. [Epub ahead of print]
    • Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol 2014 Sep 10. [Epub ahead of print]
    • (2014) J Cell Physiol
    • Roy, A.1    Banerjee, S.2
  • 63
    • 85027918531 scopus 로고    scopus 로고
    • Novel myelofibrosis treatment strategies: Potential partners for combination therapies
    • Jun 3. [Epub ahead of print]
    • Stein BL, Swords R, Hochhaus A, et al. Novel myelofibrosis treatment strategies: potential partners for combination therapies. Leukemia 2014 Jun 3. [Epub ahead of print]
    • (2014) Leukemia
    • Stein, B.L.1    Swords, R.2    Hochhaus, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.